SG11202004925QA - Novel compounds and pharmaceutical compositions thereof for the treatment of diseases - Google Patents
Novel compounds and pharmaceutical compositions thereof for the treatment of diseasesInfo
- Publication number
- SG11202004925QA SG11202004925QA SG11202004925QA SG11202004925QA SG11202004925QA SG 11202004925Q A SG11202004925Q A SG 11202004925QA SG 11202004925Q A SG11202004925Q A SG 11202004925QA SG 11202004925Q A SG11202004925Q A SG 11202004925QA SG 11202004925Q A SG11202004925Q A SG 11202004925QA
- Authority
- SG
- Singapore
- Prior art keywords
- diseases
- treatment
- pharmaceutical compositions
- novel compounds
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720101.3A GB201720101D0 (en) | 2017-12-02 | 2017-12-02 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| GBGB1817343.5A GB201817343D0 (en) | 2018-10-25 | 2018-10-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| PCT/EP2018/082537 WO2019105886A1 (en) | 2017-12-02 | 2018-11-26 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004925QA true SG11202004925QA (en) | 2020-06-29 |
Family
ID=64564856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004925QA SG11202004925QA (en) | 2017-12-02 | 2018-11-26 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
Country Status (24)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| MX2020005423A (es) * | 2017-12-02 | 2020-08-27 | Galapagos Nv | Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades. |
| JP7568512B2 (ja) | 2018-05-04 | 2024-10-16 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の塩 |
| IL312465A (en) | 2018-05-04 | 2024-06-01 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| GB201907616D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases |
| GB201907558D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US12012409B2 (en) * | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| BR112022020423A2 (pt) * | 2020-04-08 | 2022-11-29 | Remix Therapeutics Inc | Compostos e métodos para modulação de splicing |
| EP4192459A4 (en) * | 2020-08-05 | 2024-12-04 | The General Hospital Corporation | SALT-INDUCABLE KINASE INHIBITORS |
| CN112010860B (zh) * | 2020-08-05 | 2023-03-10 | 南京纳丁菲医药科技有限公司 | 苄氧基吡唑并嘧啶化合物和药物组合物及其应用 |
| MX2023003677A (es) * | 2020-09-30 | 2023-06-22 | Fl2022 001 Inc | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. |
| CN116507627A (zh) | 2020-11-02 | 2023-07-28 | 勃林格殷格翰国际有限公司 | 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物 |
| US20240158392A1 (en) * | 2021-02-01 | 2024-05-16 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| WO2022165530A1 (en) * | 2021-02-01 | 2022-08-04 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| KR20230053049A (ko) * | 2021-10-13 | 2023-04-21 | 서울대학교산학협력단 | 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품 |
| CN118119619A (zh) * | 2021-10-18 | 2024-05-31 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| AR128280A1 (es) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | Derivados de bencimidazol piridina |
| AR128279A1 (es) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | Nuevos derivados de bencimidazol piridina |
| US20250171438A1 (en) * | 2022-02-28 | 2025-05-29 | Agios Pharmaceuticals, Inc. | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations |
| CN119095854A (zh) * | 2022-02-28 | 2024-12-06 | 安吉奥斯医药品有限公司 | 用于稳定苯丙氨酸羟化酶突变的化合物和方法 |
| CN117843634A (zh) * | 2022-05-24 | 2024-04-09 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| CN119604503A (zh) * | 2022-07-01 | 2025-03-11 | 豪夫迈·罗氏有限公司 | 咪唑并[4,5-b]吡啶和吡唑并[1,5-a]嘧啶衍生物作为sik调节剂用于类风湿性关节炎的治疗 |
| US20240124450A1 (en) | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| WO2024141444A1 (en) * | 2022-12-27 | 2024-07-04 | F. Hoffmann-La Roche Ag | New benzimidazole derivatives |
| WO2024242169A1 (ja) * | 2023-05-24 | 2024-11-28 | 田辺三菱製薬株式会社 | 塩誘導性キナーゼ阻害化合物及びそれを含む医薬組成物 |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| WO2025017041A1 (en) * | 2023-07-19 | 2025-01-23 | F. Hoffmann-La Roche Ag | Benzimidazoles as sik-activity modulators |
| TW202517630A (zh) | 2023-07-19 | 2025-05-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎苯并咪唑吡啶衍生物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2178375B1 (en) * | 2007-07-20 | 2014-09-24 | Merck Sharp & Dohme Corp. | Pyrazoloý1,5-a¨pyrimidine derivatives |
| CN101765442B (zh) | 2007-07-26 | 2014-09-17 | 诺华股份有限公司 | 有机化合物 |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| US8455477B2 (en) * | 2008-08-05 | 2013-06-04 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
| GB201204384D0 (en) * | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| MX2018002631A (es) | 2015-09-03 | 2019-02-07 | Univ Arizona | Inhibidores de molecula pequeña de dyrkia y usos de los mismos. |
| MX2020005423A (es) * | 2017-12-02 | 2020-08-27 | Galapagos Nv | Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades. |
| EP4192459A4 (en) | 2020-08-05 | 2024-12-04 | The General Hospital Corporation | SALT-INDUCABLE KINASE INHIBITORS |
-
2018
- 2018-11-26 MX MX2020005423A patent/MX2020005423A/es unknown
- 2018-11-26 BR BR112020010364-0A patent/BR112020010364A2/pt unknown
- 2018-11-26 AU AU2018374456A patent/AU2018374456B2/en active Active
- 2018-11-26 MA MA051200A patent/MA51200A/fr unknown
- 2018-11-26 MY MYPI2020002758A patent/MY201849A/en unknown
- 2018-11-26 CA CA3084090A patent/CA3084090A1/en active Pending
- 2018-11-26 SG SG11202004925QA patent/SG11202004925QA/en unknown
- 2018-11-26 JP JP2020529717A patent/JP7326276B2/ja active Active
- 2018-11-26 PL PL18811769T patent/PL3717471T3/pl unknown
- 2018-11-26 HU HUE18811769A patent/HUE057581T2/hu unknown
- 2018-11-26 ES ES18811769T patent/ES2908283T3/es active Active
- 2018-11-26 KR KR1020207019014A patent/KR102720958B1/ko active Active
- 2018-11-26 PH PH1/2020/550725A patent/PH12020550725B1/en unknown
- 2018-11-26 PT PT188117691T patent/PT3717471T/pt unknown
- 2018-11-26 EP EP18811769.1A patent/EP3717471B1/en active Active
- 2018-11-26 WO PCT/EP2018/082537 patent/WO2019105886A1/en active IP Right Grant
- 2018-11-26 CN CN201880077841.9A patent/CN111433200B/zh active Active
- 2018-11-26 US US16/768,825 patent/US11339166B2/en active Active
- 2018-11-26 DK DK18811769.1T patent/DK3717471T3/da active
- 2018-11-30 TW TW107142872A patent/TW201930301A/zh unknown
-
2020
- 2020-05-26 IL IL274938A patent/IL274938B2/en unknown
- 2020-06-30 CO CONC2020/0008066A patent/CO2020008066A2/es unknown
- 2020-07-01 ZA ZA2020/04025A patent/ZA202004025B/en unknown
-
2022
- 2022-03-02 CY CY20221100182T patent/CY1125044T1/el unknown
- 2022-04-13 US US17/719,653 patent/US12065443B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| ZA202110597B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201720163D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| IL261444A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| IL271807A (en) | New compounds and their pharmaceutical preparations for the treatment of leprosy | |
| ZA202002166B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| IL257336B (en) | Pharmaceutical compounds and preparations for the prevention or treatment of parasitic diseases | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| IL285751A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| PL3586832T3 (pl) | Kompozycja farmaceutyczna do leczenia zaparcia | |
| GB201720101D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201817343D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201817344D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| HK40037090A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201809836D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
| HK40050861A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| HK40014675A (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases | |
| GB201714241D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
| GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
| GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201719584D0 (en) | Pharmaceutical compositions for the treatment of cancer |